Combined Treatment with Stattic and Docetaxel Alters the Bax/Bcl-2 Gene Expression Ratio in Human Prostate Cancer Cells

  • Mohammadian, Jamal (Drug Applied Research Center, Department of Medical Biotechnology, Tabriz University of Medical Sciences) ;
  • Sabzichi, Mehdi (Drug Applied Research Center, Department of Medical Biotechnology, Tabriz University of Medical Sciences) ;
  • Molavi, Ommoleila (Biotechnology Research Center, Tabriz University of Medical Sciences) ;
  • Shanehbandi, Dariush (Immunology Research Center, Tabriz University of Medical Sciences) ;
  • Samadi, Nasser (Drug Applied Research Center, Department of Medical Biotechnology, Tabriz University of Medical Sciences)
  • Published : 2016.11.01


Docetaxel, recognized as a stabilizing microtubule agent, is frequently administrated as a first line treatment for prostate cancers. Due to high side effects of monotherapy, however, combinations with novel adjuvants have emerged as an alternative strategy in cancer therapy protocols. Here, we investigated the combined effects of stattic and docetaxel on the DU145 prostate cancer cell line. Cytotoxicity was evaluated by MTT assay. To understand molecular mechanisms of stattic action, apoptotic related genes including Bcl-2, Mcl-1, Survivin and Bax were evaluated by real-time RT-PCR. Alteration in the expression of pro-apoptotic Bax and anti-apoptotic Bcl-2 genes and Bax/Bcl-2 ratio were investigated via the $2^{{\Delta}{\Delta}CT}$ method. The $IC_{50}$ values for docetaxel and stattic were $3.7{\pm}0.9nM$ and $4.6{\pm}0.8{\mu}M$, respectively. Evaluation of key gene expression levels revealed a noticeable decrease in antiapoptotic Bcl-2 and Mcl-1 along with an increase in pro-apoptotic Bax mRNA levels (p<0.05). Our results suggest that combination of a STAT3 inhibitor with doctaxel can be considered as a potent strategy for induction of apoptosis via increasing Bax mRNA expression.


Supported by : Tabriz University of Medical Sciences


  1. Albini A, DeCensi A, Cavalli F, Costa A (2016). Cancer prevention and interception: a new era for chemopreventive approaches. Clin Cancer Res, 17, 4322-7.
  2. Armat M, Bakhshaiesh TO, Sabzichi M, et al (2016). The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line. Bosn J Basic Med Sci, 16, 28.
  3. Czabotar PE, Lessene G, Strasser A, Adams JM (2014). Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol, 15, 49-63.
  4. Del Principe MI, Dal Bo M, Bittolo T, et al (2016). Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. Haematologica, 101, 77-85.
  5. Fabre B, Grosman H, Gonzalez D, et al (2016). Prostate cancer, high cortisol levels and complex hormonal interaction. Asian Pac J Cancer Prev, 17, 3167.
  6. Fiandalo M, Kyprianou N (2012). Caspase control: protagonists of cancer cell apoptosis. Exp Oncol, 34, 165.
  7. Fizazi K, Higano CS, Nelson GB, et al (2013). Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol, 31,1740-47.
  8. Huang F, Yang Z, Yu D, et al (2012). Sepia ink oligopeptide induces apoptosis in prostate cancer cell lines via caspase-3 activation and elevation of Bax/Bcl-2 ratio. Mar Drugs, 10, 2153-65.
  9. Jahanafrooz Z, Motameh N, Bakhshandeh B (2015). Comparative evaluation of silibinin effects on cell cycling and apoptosis in human breast cancer MCF-7 and T47D cell lines. Asian Pac J Cancer Prev, 17, 2661-65.
  10. Kamran MZ, Patil P, Gude RP (2013). Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int, 2013.
  11. Lee JS, Jung WK, Jeong MH, Yoon TR, Kim HK (2012). Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway. Int J Toxicol, 31, 70-7.
  12. Minaei A, Sabzichi M, Ramezani F, Hamishehkar H, Samadi N (2016). Co-delivery with nano-quercetin enhances doxorubicin-mediated cytotoxicity against MCF-7 cells. Mol Biol Rep, 43, 99-105.
  13. Pan Y, Zhou F, Zhang R, Claret FX (2013). Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo-and radio-sensitivity in nasopharyngeal carcinoma. PloS One 8, e54565.
  14. Park KW, Kundu J, Chae IG, et al (2014). Carnosol induces apoptosis through generation of ROS and inactivation of STAT3 signaling in human colon cancer HCT116 cells. Int J Oncol, 44, 1309-15.
  15. Pirouzpanah MB, Sabzichi M, Pirouzpanah S, Chavoshi H, Samadi N (2014). Silibilin-induces apoptosis in breast cancer cells by modulating p53, p21, Bak and Bcl-XL pathways. Asian Pac J Cancer Prev, 16, 2087-92.
  16. Renault TT, Teijido O, Antonsson B, Dejean LM, Manon S (2013). Regulation of bax mitochondrial localization by Bcl-2 and Bcl-x L: keep your friends close but your enemies closer. Int J Biochem Cell Biol, 45, 64-67.
  17. Sabzichi M, Samadi N, Mohammadian J, et al (2016). Sustained release of melatonin: A novel approach in elevating efficacy of tamoxifen in breast cancer treatment. Colloids Surf B Biointerfaces, 145, 64-71.
  18. Saini U, Naidu S, ElNaggar A, et al (2016). Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene, doi: 10.1038/onc.2016.197.
  19. Samadi N, Ghanbari P, Mohseni M, et al (2014). Combination therapy increases the efficacy of docetaxel, vinblastine and tamoxifen in cancer cells. J Cancer Res Ther, 10, 715.
  20. Sharifi S, Barar J, Hejazi MS, Samadi N (2015). Doxorubicin changes Bax/Bcl-xL ratio, caspase-8 and 9 in breast cancer cells. Adv Pharm Bull, 5, 351.
  21. Siegel RL, Miller KD, Jemal A (2015). Cancer statistics, 2015. CA Cancer J Clin, 65, 5-29.
  22. Siveen KS, Sikka S, Surana R, et al (2014). Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta, 1845, 136-54.
  23. Sonpavde G, Matveev V, Burke J, et al (2012). Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castrationresistant prostate cancer. Ann Oncol, 23, 1803-08.
  24. Su M, Mei Y, Sinha S (2013). Role of the crosstalk between autophagy and apoptosis in cancer. J Oncol, 2013.
  25. Sui X, Kong N, Ye L, et al (2014). p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett, 344, 174-79.
  26. Sun X, Bao J, Nelson KC, et al (2013). Systems modeling of anti-apoptotic pathways in prostate cancer: psychological stress triggers a synergism pattern switch in drug combination therapy. PLoS Comput Biol, 9, e1003358.
  27. Swain SM, Baselga J, Kim SB, et al (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med, 372, 724-34.
  28. Thomas S, Quinn BA, Das SK, et al (2013). Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets, 17, 61-75.
  29. Tupal A, Sabzichi M, Ramezani F, Kouhsoltani M, Hamishehkar H (2016). Dermal delivery of doxorubicin-loaded solid lipid nanoparticles for the treatment of skin cancer. J Microencapsul, 33, 372-80.
  30. von Minckwitz G (2007). Docetaxel/anthracycline combinations for breast cancer treatment. Expert Opin Pharmacother, 8, 485-95.
  31. Wang F, Zhu Y, Fang S, Li S, Liu S (2016). Lanthanum chloride enhances cisplatin-induced apoptosis in ovarian cancer cells. Cell Mol Biol, 62, 1.
  32. Yu H, Lee H, Herrmann H, Buettner R, Jove R (2014). Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer, 14, 736-46.
  33. Zhang J, Du J, Liu Q, Zhang Y (2015). Down-regulation of STAT3 expression using vector-based RNA interference promotes apoptosis in Hepatocarcinoma cells. Artif Cells Nanomed Biotechnol, 44, 1201-5.
  34. Zhang Q, Zhang C, He J, et al (2015).STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma. Tumor Biol, 36, 2135-42.
  35. Zhang X, Bi L, Ye Y, Chen J (2014).Formononetin induces apoptosis in PC-3 prostate cancer cells through enhancing the Bax/Bcl-2 ratios and regulating the p38/Akt pathway. Nutr Cancer, 66, 656-61.